At ESMO 2025 in Berlin, pharmaphorum spoke with Tadaaki Taniguchi, Chief Research & Development Officer at Astellas, about ...

MSD has announced a takeover deal for Cidara Therapeutics, an infectious disease specialist currently focused on developing a ...

In a statement, Avadel acknowledged that it had received the Lundbeck bid and that its board of directors had "determined in ...

Kura Oncology has claimed FDA approval for oral menin inhibitor Komzifti for a form of acute myeloid leukaemia (AML), making ...

On World Diabetes Day, Sanofi is celebrating an approval recommendation in the EU for Teizeild, a first-in-class drug ...

This World Diabetes Day, Sanofi UK and DigiBete are hosting a pop-up event in Leeds today and tomorrow, 14th & 15th November, ...

Anglo-Swiss life sciences investment company Medicxi has raised €500 million (around $579 million) for its sixth fund, which will focus on supporting 'asset-centric' companies at all stages of drug ...

The study of GanLum (KLU156) – a combination of novel drug ganaplacide with established antimalarial lumefantrine – showed ...

Alkermes already has positive results for alixorexton in NT1 from the phase 2 Vibrance-1, while Takeda is developing another ...

For the Financial Times (FT) Global Pharma & Biotech Summit in London 2025, pharmaphorum is providing coverage courtesy of ...

The $6.7 billion merger brought together two companies that had been forced to file for bankruptcy protection due to opioid ...